OR WAIT 15 SECS
FDA seeks comments on behind-the-counter drugs
The FDA has posted a notice in the Oct. 3 Federal Register, announcing a public meeting on Nov. 14 to obtain comments regarding behind-the-counter (BTC) availability of drugs. The purpose of the meeting is to solicit information and views on specific issues associated with BTC availability, including increased patient access to safe and effective drug products. The agency is interested in obtaining public comments as it explores the public health benefit of certain drugs being available BTC without a prescription, but only after intervention by a pharmacist.